Are you Dr. Chakravarthy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Robert Wood Johnson Pl
# MEB384
New Brunswick, NJ 08901Phone+1 732-235-7749Fax+1 314-747-8963
Summary
- Dr. Manu Chakravarthy, MD is an endocrinologist in New Brunswick, New Jersey. He is currently licensed to practice medicine in New Jersey, Missouri, and Pennsylvania.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2003
McGovern Medical School at UTHealthClass of 2001
Certifications & Licensure
NJ State Medical License 2009 - 2025
MO State Medical License 2006 - 2016
PA State Medical License 2001 - 2003
Publications & Presentations
PubMed
- Editorial: Mitochondrial Biology and Its Role in Metabolic Diseases.Jochen G Schneider, Effie Tozzo, Manu V Chakravarthy
Frontiers in Endocrinology. 2022-01-01 - 11 citationsSafety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.Stephen A. Harrison, Seth J. Baum, Nadege Gunn, Ziad Younes, Anita Kohli
The American Journal of Gastroenterology. 2021-08-12 - 8 citationsA novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human...Daou Nadine, Andreu Viader, Murat Cokol, Arianna Nitzel, Manu V. Chakravarthy
Scientific Reports. 2021-06-04
Press Mentions
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 DiabetesMay 4th, 2021- Carmot Therapeutics Expands Leadership Team with Appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&DMarch 17th, 2021
- Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 MilestonesJanuary 11th, 2021
- Join now to see all
Grant Support
- Identification Of The Physiologically Relevant Endogenous Ligand For Ppar?National Center For Research Resources2009–2011
- ?New" Hepatic Fat Activates Ppar? To Maintain Glucose, Lipid, And CholesterolNational Center For Research Resources2007
- New Hepatic Fat Activates Ppara To Maintain Glucose Lipid Cholesterol HomeoNational Center For Research Resources2006–2007
